• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

    0.0674 -0.0057 (-7.80%)
    Streaming Delayed Price Updated: 11:03 AM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,096,831
    Open 0.0720
    Bid (Size) 0.0673 (1,000)
    Ask (Size) 0.0675 (900)
    Prev. Close 0.0731
    Today's Range 0.0660 - 0.0740
    52wk Range 0.0651 - 2.100
    Shares Outstanding 15,859,280
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
    Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
    From Propanc Biopharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -88.2%
    -88.2%
    1 Month
    -30.9%
    -30.9%
    3 Month
    -70.8%
    -70.8%
    6 Month
    -91.4%
    -91.4%
    1 Year
    -96.3%
    -96.3%

    More News

    Read More
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From Rosen Law Firm
    Via Business Wire
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    Unusual volume stocks in Friday's session ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Top movers in Thursday's session ↗
    Via Chartmill
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Thursday. ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Which stocks are moving after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Shareholder Update
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
    From Propanc Biopharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Propanc Biopharma, Inc. - Common Stock publicly traded?
    Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
    Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
    The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
    What is the current price of Propanc Biopharma, Inc. - Common Stock?
    The current price of Propanc Biopharma, Inc. - Common Stock is 0.0674
    When was Propanc Biopharma, Inc. - Common Stock last traded?
    The last trade of Propanc Biopharma, Inc. - Common Stock was at 05/15/26 11:03 AM ET
    What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
    The market capitalization of Propanc Biopharma, Inc. - Common Stock is 1.07M
    How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
    Propanc Biopharma, Inc. - Common Stock has 1M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.